Mesa Laboratories, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59064R1095
USD
78.98
1.02 (1.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Mesa Laboratories, Inc.
Artivion, Inc.
IRadimed Corp.
BioLife Solutions, Inc.
Varex Imaging Corp.
Silk Road Medical, Inc.
OrthoPediatrics Corp.
Atrion Corp.
Cytek Biosciences, Inc.
Nevro Corp.
Minerva Surgical, Inc.

Why is Mesa Laboratories, Inc. ?

1
Company has a low Debt to Equity ratio (avg) at times
2
With a growth in Net Profit of 46.61%, the company declared Very Positive results in Dec 25
  • The company has declared positive results in Jan 70 after 2 consecutive negative quarters
  • NET PROFIT(Q) At USD 3.63 MM has Grown at 1,023.66%
  • ROCE(HY) Highest at 2.18%
  • INVENTORY TURNOVER RATIO(HY) Highest at 4.1 times
3
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Mesa Laboratories, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Mesa Laboratories, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Mesa Laboratories, Inc.
-37.41%
-0.34
61.80%
S&P 500
18.81%
0.98
19.26%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
13.72%
EBIT Growth (5y)
6.39%
EBIT to Interest (avg)
1.25
Debt to EBITDA (avg)
3.77
Net Debt to Equity (avg)
0.96
Sales to Capital Employed (avg)
0.61
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.60%
ROE (avg)
3.49%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
117
Industry P/E
Price to Book Value
2.34
EV to EBIT
33.51
EV to EBITDA
13.67
EV to Capital Employed
1.76
EV to Sales
2.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.26%
ROE (Latest)
2.00%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

26What is working for the Company
NET PROFIT(Q)

At USD 3.63 MM has Grown at 1,023.66%

ROCE(HY)

Highest at 2.18%

INVENTORY TURNOVER RATIO(HY)

Highest at 4.1 times

INTEREST COVERAGE RATIO(Q)

Highest at 450.92

PRE-TAX PROFIT(Q)

At USD 4.6 MM has Grown at 153.4%

RAW MATERIAL COST(Y)

Fallen by -2.02% (YoY

NET SALES(Q)

Highest at USD 65.13 MM

OPERATING PROFIT(Q)

Highest at USD 13.69 MM

OPERATING PROFIT MARGIN(Q)

Highest at 21.02 %

-4What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD 41.52 MM

CASH AND EQV(HY)

Lowest at USD 49.4 MM

INTEREST(Q)

Highest at USD 3.04 MM

Here's what is working for Mesa Laboratories, Inc.

Net Profit
At USD 3.63 MM has Grown at 1,023.66%
over average net sales of the previous four periods of USD -0.39 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Interest Coverage Ratio
Highest at 450.92
in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Pre-Tax Profit
At USD 4.6 MM has Grown at 153.4%
over average net sales of the previous four periods of USD 1.81 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Inventory Turnover Ratio
Highest at 4.1 times and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales
Highest at USD 65.13 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 13.69 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at 21.02 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Raw Material Cost
Fallen by -2.02% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Mesa Laboratories, Inc.

Operating Cash Flow
Lowest at USD 41.52 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest
Highest at USD 3.04 MM
in the last five periods and Increased by 6.08% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv
Lowest at USD 49.4 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents